EA200201068A1 - Способ и композиция для лечения рака введением химиотерапевтических средств, вызывающих апоптоз - Google Patents

Способ и композиция для лечения рака введением химиотерапевтических средств, вызывающих апоптоз

Info

Publication number
EA200201068A1
EA200201068A1 EA200201068A EA200201068A EA200201068A1 EA 200201068 A1 EA200201068 A1 EA 200201068A1 EA 200201068 A EA200201068 A EA 200201068A EA 200201068 A EA200201068 A EA 200201068A EA 200201068 A1 EA200201068 A1 EA 200201068A1
Authority
EA
Eurasian Patent Office
Prior art keywords
chemotherapeutic agent
tumor
composition
microspheres
introduction
Prior art date
Application number
EA200201068A
Other languages
English (en)
Inventor
Моше Флэшнер-Барек
Original Assignee
Тева Фармасьютикал Индастриес Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Тева Фармасьютикал Индастриес Лтд. filed Critical Тева Фармасьютикал Индастриес Лтд.
Publication of EA200201068A1 publication Critical patent/EA200201068A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Pyrane Compounds (AREA)

Abstract

Данное изобретение относится к противоопухолевому химиотерапевтическому средству для больных с опухолью, к композиции, содержащей микросферы, включающие противоопухолевое химиотерапевтическое средство и суспендирующий раствор, который окружает микросферы. Данное изобретение также относится к способу введения противоопухолевого химиотерапевтического средства больным с опухолью, включающему стадии доставки противоопухолевого химиотерапевтического средства в виде резервуара химиотерапевтического средства к опухоли и высвобождение противоопухолевого химиотерапевтического средства из резервуара химиотерапевтического средства в интерстициальную область опухоли в терапевтически эффективном количестве, причем резервуар химиотерапевтического средства включает микросферы, содержащие противоопухолевое химиотерапевтическое средство и суспендирующий раствор, который окружает микросферы.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200201068A 2000-04-10 2001-04-10 Способ и композиция для лечения рака введением химиотерапевтических средств, вызывающих апоптоз EA200201068A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19592000P 2000-04-10 2000-04-10
PCT/US2001/011688 WO2001076567A1 (en) 2000-04-10 2001-04-10 Method and composition for treating cancer by administration of apoptosis-inducing chemotherapeutic agents

Publications (1)

Publication Number Publication Date
EA200201068A1 true EA200201068A1 (ru) 2003-12-25

Family

ID=22723363

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200201068A EA200201068A1 (ru) 2000-04-10 2001-04-10 Способ и композиция для лечения рака введением химиотерапевтических средств, вызывающих апоптоз

Country Status (19)

Country Link
US (1) US20020041888A1 (ru)
EP (1) EP1274404A1 (ru)
JP (1) JP2004507451A (ru)
KR (1) KR20030008368A (ru)
CN (1) CN1438882A (ru)
AU (1) AU2001253334A1 (ru)
BR (1) BR0110150A (ru)
CA (1) CA2406484A1 (ru)
CZ (1) CZ20023333A3 (ru)
EA (1) EA200201068A1 (ru)
HU (1) HUP0302296A2 (ru)
IL (1) IL152180A0 (ru)
MX (1) MXPA02009984A (ru)
NO (1) NO20024867L (ru)
PL (1) PL366035A1 (ru)
SK (1) SK14452002A3 (ru)
WO (1) WO2001076567A1 (ru)
YU (1) YU77002A (ru)
ZA (1) ZA200208167B (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20020680A1 (it) * 2002-03-29 2003-09-29 Acs Dobfar Spa Composizione antitumorale migliorata a base di paclitaxel e metodo per il suo ottenimento
ITMI20020681A1 (it) * 2002-03-29 2003-09-29 Acs Dobfar Spa Procedimento per la produzione di nanoparticelle di paclitaxel ed albumina
EP1499299A2 (en) * 2002-04-26 2005-01-26 Teva Pharmaceutical Industries Ltd. Microparticle pharmaceutical compositions for intratumoral delivery
CN1319525C (zh) * 2004-09-16 2007-06-06 北京圣医耀科技发展有限责任公司 紫杉醇－海藻酸钠微球血管栓塞剂及其制备
KR100912307B1 (ko) * 2004-10-21 2009-08-14 유니버시티 오브 아이오와 리써치 파운데이션 동일계내 제어된 방출 약물 전달 시스템
PT1853250E (pt) 2005-02-18 2012-02-03 Abraxis Bioscience Llc Combinações e modos de administração de agentes terapêuticos e terapia de combinação
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
WO2006117220A2 (en) 2005-05-04 2006-11-09 Medigene Ag Method of administering a cationic liposomal preparation comprising paclitaxel
RU2448697C2 (ru) 2006-03-22 2012-04-27 Медигене Аг Лечение рака молочной железы, негативного по трем рецепторам
NZ717490A (en) 2010-03-29 2017-12-22 Abraxis Bioscience Llc Methods of treating cancer
CN107158389A (zh) 2010-03-29 2017-09-15 阿布拉科斯生物科学有限公司 增强药物递送和治疗剂有效性的方法
AU2011261685B2 (en) 2010-06-04 2016-02-11 Abraxis Bioscience, Llc Methods of treatment of pancreatic cancer
EP2661281B1 (en) 2011-01-09 2021-03-10 ANP Technologies, Inc. Hydrophobic molecule-induced branched polymer aggregates and their use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4345588A (en) * 1979-04-23 1982-08-24 Northwestern University Method of delivering a therapeutic agent to a target capillary bed
US4492720A (en) * 1983-11-15 1985-01-08 Benjamin Mosier Method of preparing microspheres for intravascular delivery
HUP9701554D0 (en) * 1997-09-18 1997-11-28 Human Oltoanyagtermeloe Gyogys Pharmaceutical composition containing plazma proteins

Also Published As

Publication number Publication date
YU77002A (sh) 2005-09-19
CZ20023333A3 (cs) 2003-06-18
MXPA02009984A (es) 2004-09-10
US20020041888A1 (en) 2002-04-11
IL152180A0 (en) 2003-05-29
EP1274404A1 (en) 2003-01-15
KR20030008368A (ko) 2003-01-25
NO20024867D0 (no) 2002-10-09
CA2406484A1 (en) 2001-10-18
CN1438882A (zh) 2003-08-27
AU2001253334A1 (en) 2001-10-23
ZA200208167B (en) 2004-02-10
PL366035A1 (en) 2005-01-24
BR0110150A (pt) 2004-04-27
SK14452002A3 (sk) 2003-07-01
HUP0302296A2 (hu) 2003-10-28
WO2001076567A1 (en) 2001-10-18
NO20024867L (no) 2002-12-06
JP2004507451A (ja) 2004-03-11

Similar Documents

Publication Publication Date Title
EA200700686A1 (ru) Липосомы, включающие радиоактивный изотоп, и цитотоксический агент для комбинированной терапии
EA200201068A1 (ru) Способ и композиция для лечения рака введением химиотерапевтических средств, вызывающих апоптоз
MX339142B (es) Combinaciones y metodos de administracion de agentes terapeuticos y terapia de combinacion.
HK1120427A1 (en) Anti-glypican-3 antibody
UY26456A1 (es) Compuestos que fijan la estructura g-cuadruplex de los telomeros, triazinas de aplicación de dichos compuestos, la utilización de dichos compuestos como productos farmacéuticos y las asociaciones terapéuticas que los incluyen.
BR0209147A (pt) Terapia combinada que usa anticorpos anti-egfr e agentes anti-hormonais
MXPA06010667A (es) Metodos combinatorios y composiciones para el tratamiento de melanoma.
MX336710B (es) Oligoribonucleotidos y metodos de uso de los mismos para tratamiento de la alopecia, insuficiencia renal aguda y otras enfermedades.
DK1169059T3 (da) Docetaxel i kombination med rhuMAb HER2 til behandling af cancere
RU94034104A (ru) Способ увеличения цитотоксичности химиотерапевтического агента, набор для лечения и средство для производства лекарств
BR0111438A (pt) Análogos de ácido barbitúrico como agentes terapeuticos
MX2007003506A (es) Terapia de combinacion de cancer que comprende azd2171 e imatinib.
PL365285A1 (en) Pharmaceutical combinations for the treatment of cancer comprising dioxolane nucleoside analogs
BR0213424A (pt) Uso aperfeiçoado de composto antitumoral na terapia contra câncer
ATE413180T1 (de) Methylation-modulierende verbingungen zur intraduktalen behandlung von brustkrebs
RU2225710C2 (ru) Списулозиновые соединения, обладающие противоопухолевой активностью
EP1545479A4 (en) EZETIMIB COMPOSITIONS AND METHOD FOR THE TREATMENT OF CHOLESTERIN-ASSOCIATED GOOD AND EVIL TUMORS
EP1427418A4 (en) PIPERAZINONE COMPOUNDS AS ANTITUMOR AND ANTICANCER AGENTS AND METHODS OF TREATMENT
NO20064754L (no) Kombinasjonsterapi
RU2335539C2 (ru) Фармацевтический препарат и способ лечения злокачественных опухолей у человека с помощью аргининовой депривации
DE60222383D1 (de) Medikament zur verabreichung von amifostin und verwandten wirkstoffen
SV2002000179A (es) Proceso para la preparacion de un compuesto para reducir el riesgo del cancer ref.x-13527-el
BR9808263A (pt) Processos para tratar câncer em um humano em necessidade de tratamento e para manufaturar um medicamento para inibir o crescimento em um humano de um tumor sólido, e, uso de um composto.
WO2000006136A3 (en) Therapeutic combination of polyamine with an anticancer agent
KR960700734A (ko) 사람 암에 대한 시스플래틴/타목시펜 배합 치료(Combination cisplatin/tamoxifen therapy for human cancers)